Progress on new vaccine strategies for the immunotherapy and prevention of cancer

Journal of Clinical Investigation

Volumn 113, Issue 11, 2004, Pages 1515-1525

  Berzofsky, Jay A ^a   Terabe, Masaki ^a   Oh, SangKon ^a   Belyakov, Igor M ^a   Ahlers, Jeffrey D ^b   Janik, John E ^a   Morris, John C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIGEN MODIFIED DENDRITIC CELL VACCINE; CANCER VACCINE; CHEMOKINE; CYTOKINE; DENDRITIC CELL VACCINE; DNA VACCINE; EPITOPE; GENE MODIFIED TUMOR CELL VACCINE; MODIFIED TUMOR CELL VACCINE; PEPTIDE VACCINE; PLASMID DNA; TUMOR ANTIGEN; UNCLASSIFIED DRUG; VACCINE; VIRUS VECTOR; WHOLE TUMOR CELL VACCINE; SUBUNIT VACCINE;

CANCER CELL; CANCER PREVENTION; CANCER THERAPY; DRUG EFFICACY; IMMUNE SYSTEM; IMMUNOGENICITY; IMMUNOSURVEILLANCE; IMMUNOTHERAPY; PRIORITY JOURNAL; RECOMBINANT VIRAL VECTOR; REVIEW; VACCINATION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRAL GENE TRANSFER VECTOR; VIRUS RECOMBINANT; GENE VECTOR; HUMAN; IMMUNOLOGY; NEOPLASM; VIRUS;

ANTIGENS, NEOPLASM; CANCER VACCINES; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; NEOPLASMS; VACCINES, DNA; VACCINES, SUBUNIT; VIRUSES;

EID: 85047694751     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI21926     Document Type: Review

References (125)

1. Henderson, R.A., and Finn, O.J. 1996. Human tumor antigens are ready to fly. Adv. Immunol. 62:217-256.
2. Disis, M.L., and Cheever, M.A. 1996. Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. 8:637-642.
3. Wang, R.-F., and Rosenberg, S.A. 1999. Human tumor antigens for cancer vaccine development. Immunol. Rev. 170:85-100.
4. Berzofsky, J.A., Ahlers, J.D., and Belyakov, I.M. 2001. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol 1:209-219.
5. Yu, Z., and Restifo, N.P. 2002. Cancer vaccines: progress reveals new complexities. J. Clin. Invest. 110:289-294. doi:10.1172/JCI200216216.
6. Parmiani, G., et al. 2002. Cancer immunotherapy with peptide-based vaccines: what have we achieved? where are we going? J. Natl. Cancer, Inst. 94:805-818.
7. Salit, R.B., Kast, W.M., and Velders, M.P. 2002. Ins and outs of clinical trials with peptide-based vaccines. Front. Biosci. 7:e204-e213.
8. Berzofsky, J.A., and Berkower, I.J. 2003. Immunogenicity and antigen structure. In Fundamental immunology. W.E. Paul, editor. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 631-683.
9. Germain, R.N., and Margulies, D.H. 1993. The biochemistry and cell biology of antigen processing and presentation. Annu. Rev. Immunol. 11:403-450.
10. Rosenberg, A.S., and Singer, A. 1992. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction. Ann. Rev. Immunol. 10:333-358.
11. Waldmann, T.A. 2003. Immunotherapy: past, present and future. Nat. Med. 9:269-277.
12. Hung, K., et al. 1998. The central role of CD4(+) T cells in the antitumor immune response. J. Exp. Med. 188:2357-2368.
13. Banchereau, J., and Steinman, R.M. 1998. Dendritic cells and the control of immunity. Nature. 392:245-252.
14. Hurwitz, A.A., Yu, T.F.-Y., Leach, D.R., and Allison, J.P. 1998. CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. U. S. A. 95:10067-10071.
15. Shimizu, J., Yamazaki, S., and Sakaguchi, S. 1999. Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163:5211-5218.
16. Sutmuller, R.P.M., et al. 2001. Synetgism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25+ regulatory T cells in antitumor therapy reveals alternative cytotoxic T lymphocyte responses. J. Exp. Med. 194:823-832.
17. Terabe, M., and Berzofsky, J.A. 2004. Immunoregulatory T cells in tumor immunity. Curr. Opin. Immunol. 16:157-162.
18. Terabe, M., et al. 2000. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat. Immunol 1:515-520.
19. Terabe, M., et al. 2003. Transforming growth factor-β production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence. J. Exp. Med. 198:1741-1752.
20. Renkvist, N., Castelli, C., Robbins, P.F., and Parmiani, G. 2001. A listing of human tumor antigens recognized by T cells. Cancer Immunol. Immunother. 50:3-15.
21. Berzofsky, J.A., Helman, L.J., and Carbone, D.P. 2000. Cancer vaccines: cancer antigens: oncogenes and mutations. In Principles and practice of the biologic therapy of cancer. 3rd edition. S.A. Rosenberg, editor. Lippincott Williams & Wilkins. Philadelphia, Pennsylvania, USA. 526-541.
22. Gjertsen, M.K., et al. 1995. Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding RAS mutation. Lancet. 346:1399-1400.
23. Yanuck, M., et al. 1993. A mutant p53 tumor suppressor protein is a target for peptide-induced CD8+ cytotoxic T cells. Cancer Res. 53:3257-3261.
24. Pinilla-Ibarz, J., et al. 2000. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood. 95:1781-1787.
25. Goletz, T.J., Mackall, C.L., Berzofsky, J.A., and Helman, L.J. 1998. Molecular alterations in pediatric sarcomas: potential targets for immunotherapy. Sarcoma. 2:77-87.
26. Mackall, C., Berzofsky, J., and Helman, L.J. 2000. Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy, Clin. Orthop. 25-31.
27. Worley, B.S., et al. 2001. Antigenicity of fusion proteins from sarcoma-associated chromosomal translocations. Cancer Res. 61:6868-6875.
28. Bos, J.L. 1989. ras oncogenes in human cancer: a review. Cancer Res. 49:4682-4689.
29. Chiba, I., et al. 1990. Mutations in the p53 gene are frequent in primary, resected non-small cell lung cancer. Oncogene. 5:1603-1610.
30. Smith, M.C., et al. 1997. Oncogenic mutations in ras create HLA-A2.1 binding peptides but affect their extracellular processing. Int. Immunol. 9:1085-1093.
31. Peace, D.J., et al. 1994. Lysis of Ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated Ras peptide. J. Exp. Med. 179:473-479.
32. Zaremba, S., et al. 1997. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 57:4570-4577.
33. Fong, L., et al. 2001. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 98:8809-8814.
34. Theobald, M., Biggs, J., Dittmer, D., Levine, A.J., and Sherman, L.A. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. U. S. A. 92:11993-11997.
35. Correale, P., et al. 1997. In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 89:293-300.
36. Roskrow, M.A., et al. 1998. Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin's disease. Blood. 91:2925-2934.
37. Dranoff, G., et al. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. U.S.A. 90:3539-3543.
38. Simons, J. W., et al. 1999. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59:5160-5168.
39. Soiffer, R., et al. 1998, Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 95:13141-13146.
40. Jaffee, E.M., et al. 2001. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J. Clin. Oncol. 19:145-156.
41. Salgia, R., et al. 2003. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. J. Clin. Oncol. 21:624-630.
42. Maio, M., et al. 2002. Vaccination of stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunol. Immunother. 51:9-14.
43. Antonia, S.J., et al. 2002. Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma. J. Urol. 167:1995-2000.
44. Unfer, R.C., Hellrung, D., and Link, C.J., Jr. 2003. Immunity to the alpha(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing alpha(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy. Cancer Res. 63:987-993.
45. Stern, L.J., and Wiley, D.C. 1994. Antigenic peptide binding by class I and class II histocompatibility proteins. Structure. 2:245-251.
46. Rammensee, H.-G., Friede, T., and Stevanovíc, S. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics. 41:178-228.
47. Traversari, C., et al. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453-1457.
48. Berzofsky, J.A. 1993. Epitope selection and design of synthetic vaccines: molecular approaches to enhancing immunogenicity and crossreactivity of engineered vaccines. Ann. N. Y. Acad. Sci. 690:256-264.
49. Rosenberg, S.A., et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
50. Rivoltini, L., et al. 1999. A superagonist variant of peptide MART1/Melan A27-35 elicits antimelanoma CD8+ T cells with enhanced functional characteristics: implication for more effective Immunotherapy. Cancer Res. 59:301-306.
51. Brinckerhoff, L.H.,et al. 1999. Terminal modifications inhibit proteolytic degradation of an immunogenic MART-l(27-35) peptide: implications for peptide vaccines. Int. J. Cancer. 83:326-334.
52. Ahlers, J.D., et al. 2002. A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with GM-CSF and CD40L. Proc. Natl. Acad. Sci. U. S. A. 99:13020-13025.
53. Klinman, D.M., Yi, A.K., Beaucage, S.L., Conover, J., and Krieg, A.M. 1996. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. Proc. Natl. Acad. Sci. U. S. A. 93:2879-2883.
54. Alexander, J., et al. 1994. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity. 1:751-761.
55. Shirai, M., et al. 1996. Use of intrinsic and extrinsic helper epitopes for in vivo induction of anti-hepatitis C virus cytotoxic T lymphocytes (CTL) with CTL epitope peptide vaccines. J. Infect. Dis. 173:24-31.
56. Melief, C.J., Van Der Burg, S.H., Toes, R.E., Ossendorp, F., and Ofringa, R. 2002. Effective therapeutic anticancer vaccines based on precision guiding of cytolytic T lymphocytes. Immunol. Rev. 188:177-182.
57. Ahlers, J.D., Belyakov, I.M., Thomas, E.K., and Berzofsky, J. A. 2001. High affinity T-helper epitope induces complementary helper and APC polarization, increased CTL and protection against viral infection. J. Clin. Invest. 108:1677-1685. doi:10.1172/JCI200113463.
58. Smith, J.W., 2nd, et al. 2003. Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gpl00 peptide induces peptide-specific CD8+ T-cell responses. J. Clin. Oncol. 21:1562-1573.
59. Lee, P., et al. 2001. Effects of interleukin-12 on the immune response to a multipeptide vaccine for resected metastatic melanoma. J. Clin. Oncol. 19:3836-3847.
60. Weber, J., et al. 2003. Granulocyte-macrophage-colony-stimulating factor added to a multipeptide vaccine for resected Stage II melanoma. Cancer. 97:186-200.
61. Schaed, S.G., et al. 2002. T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. Clin. Cancer Res. 8:967-972.
62. Phan, G.Q., et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. U. S. A. 100:8372-8377.
63. Marshall, J.L., et al. 2000. Phase I study in advanced cancer patients of diversified prime-and-boost vaccination protocol using recombinant vaccinia virus and recombinant nonreplicating avipox virus to elicit anti- carcinoembryonic antigen immune responses. J. Clin. Oncol. 18:3964-3973.
64. Zhu, M.Z., Marshall, J., Cole, D., Schlom, J., and Tsang, K. Y. 2000. Specific cytotoxic T-cell responses to human CEA from patients immunized with recombinant avipox-CEA vaccine. Clin. Cancer Res. 6:24-33.
65. Belyakov, I.M., Moss, B., Strober, W., and Berzofsky, J.A. 1999. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity. Proc. Natl. Acad. Sci. U. S. A. 96:4512-4517.
66. Hodge, J.W., et al. 1999. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59:5800-5807.
67. Oh, S., et al. 2003. Selective induction of high avidity CTL by altering the balance of signals from antigen presenting cells. J. Immunol. 170:2523-2530.
68. Tang, D., DeVit, M., and Johnston, S.A. 1992. Genetic immunization is a simple method for eliciting an immune response. Nature. 356:152-154.
69. Ulmer, J.B., et al. 1993. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 259:1745-1749.
70. Timmerman, J.M., et al. 2002. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma. Cancer Res. 62:5845-5852.
71. Conry, R.M., et al. 2002. Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin. Cancer Res. 8:2782-2787.
72. Fong, L., and Engleman, E.G. 2000. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18:245-273.
73. Schuler, G., Schuler-Thurner, B., and Steinman, R.M. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138-147.
74. Gabrilovich, D.I., Nadaf, S., Corak, J., Berzofsky, J.A., and Carbone, D.P. 1996. Dendritic cells in antitumor immune responses. II. Dendritic cells grown from bone marrow precursors, but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol. 170:111-119.
75. Gabrilovich, D.I.,et al. 1996. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells [erratum 1996, 2:1267]. Nat. Med. 2:1096-1103.
76. Mayordomo, J.I., et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297-1302.
77. Porgador, A., and Gilboa, E. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med. 182:255-260.
78. Nair, S.K., Snyder, D., Rouse, B.T., and Gilboa, E. 1997. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer. 70:706-715.
79. Paglia, P., Chiodoni, C., Rodolfo, M., and Colombo, M.P. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317-322.
80. Zitvogel, L., et al. 1996. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183:87-97.
81. Ashley, D.M., et al. 1997. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J. Exp. Med. 186:1177-1182.
82. Mayordomo, J.I., et al. 1996. Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med 183:1357-1365.
83. Siders, W.M., Vergilis, K.L., Johnson, C., Shields, J., and Kaplan, J.M. 2003. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol. Ther. 7:498-505.
84. Chen, H.W., et al. 2003. Inducing long-term survival with lasting anti-tumor immunity in treating B cell lymphoma by a combined dendritic cell-based and hydrodynamic plasmid-encoding IL-12 gene therapy. Int. Immunol. 15:427-435.
85. Akiyama, Y., et al. 2000. Enhancement of antitumor immunity against B16 melanoma tumor using genetically modified dendritic cells to produce cytokines. Gene Ther. 7:2113-2121.
86. Wan, Y., Bramson, J., Carter, R., Graham, F., and Gauldie, J. 1997. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination. Hum. Gene Ther. 8:1355-1363.
87. Esslinger, C., Romero, P., and MacDonald, H.R. 2002. Efficient transduction of dendritic cells and induction of a T-cell response by thitd-genetation lentivectors. Hum. Gene Ther. 13:1091-1100.
88. Bonifaz, L., et al. 2002. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196:1627-1638.
89. Caux, C., Dezutter-Dambuyant, C., Schmitt, D., and Banchereau, J. 1992. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langethans cells. Nature. 360:258-261.
90. Sallusto, F., and Lanzavecchia, A. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179:1109-1118.
91. Banchereau, J., et al. 2001. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451-6458.
92. Mackensen, A., et al. 2000. Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells. Int. J. Cancer. 86:385-392.
93. Rosenzwajg, M., Jourquin, F., Tailleux, L., and Gluckman, J.C. 2002. CD40 ligation and phagocytosis differently affect the differentiation of monocytes into dendritic cells. J. Leukoc. Biol. 72:1180-1189.
94. Labeur, M.S., et al. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:168-175.
95. Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., and Bhardwaj, N. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med 193:233-238.
96. Dhodapkar, M.V., and Steinman, R.M. 2002. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 100:174-177.
97. Jonuleit, H., Schmitt, E., Schuler, G., Knop,J., and Enk, A.H. 2000. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213-1222.
98. Steinmann, R.M., and Dhodapkar, K. 2001. Active immunization against cancer with dendritic cells. Int. J. Cancer. 94:459-573.
99. Nestle, F.O. 2000. Dendritic cell vaccination for cancer therapy. Oncogene. 19:6673-6679.
100. Hsu, F.J., et al. 1996. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2:52-58.
101. Timmerman, J.M., et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood. 99:1517-1526.
102. Reichardt, V.L., et al. 1999. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma - a feasibility study. Blood. 93:2411-2419.
103. Liso, A., et al. 2000. Idiotype vaccination using dendritic cells after autologous peripheral blood progenitor cell transplantation for multiple myeloma. Biol. Blood Marrow Transplant. 6:621-627.
104. Valone, F.H., et al. 2001. Dendritic cell-based treatment of cancer: closing in on a cellular therapy. Cancer J. 7(Suppl. 2):S53-S61.
105. Fong, L., et al. 2001. Dendritic cell-based xenoantigen vaccination for prostate cancer immunotherapy. J. Immunol 167:7150-7156.
106. Nestle, F.O., et al. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
107. Thurner, B., et al. 1999. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669-1678.
108. Stift, A., et al. 2003. Dendritic cell-based vaccination in solid cancer. J. Clin. Oncol. 21:135-142.
109. Su, Z., et al. 2003. Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. 63:2127-2133.
110. Serody, J.S., Collins, E.J., Tisch, R.M., Kuhns, J.J., and Frelinger, J.A. 2000. T cell activity after dendritic cell vaccination is dependent on both the type of antigen and the mode of delivery. J. Immunol. 164:4961-4967.
111. Egen, J.G., Kuhns, M.S., and Allison, J.P. 2002. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3:611-618.
112. Lee, K.M., et al. 1998. Molecular basis of T cell inactivation by CTLA-4. Science. 282:2263-2266.
113. Thornton, A.M., and Shevach, E.M. 2000. Suppressor effector function of CD4+CD25+ immunoregulatory T cells is antigen nonspecific. J. Immunol. 164:183-190.
114. Kronenberg, M., and Gapin, L. 2002. The unconventional lifestyle of NKT cells. Nat. Rev. Immunol. 2:557-568.
115. l15. Wilson, S.B., and Delovitch, T.L. 2003. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev. Immunol. 3:211-222.
116. Ostrand-Rosenberg, S., et al. 2002. Resistance to metastatic disease in Stat6-deficient mice requires hematopoietic and non-hematopoietic cells and is IFNγ-dependent. J. Immunol. 169:5796-5804.
117. Snyder, J.T., Alexander-Miller, M.A., Berzofsky, J.A., and Belyakov, I.M. 2003. Molecular mechanisms and biological significance of CTL avidity. Curr. HIV Res. 1:287-294.
118. Alexander-Miller, M.A., Leggatt, G.R., and Berzofsky, J.A. 1996. Selective expansion of high or low avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl. Acad. Sci. U. S. A. 93:4102-4107.
119. Yee, C., Savage, P.A., Lee, P.P., Davis, M.M., and Greenberg, P.D. 1999. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. 162:2227-2234.
120. Zeh, H.J., III, Perry-Lalley, D., Dudley, M.E., Rosenberg, S.A., and Yang, J.C. 1999. High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J. Immunol. 162:989-994.
121. Oh, S., Berzofsky, J.A., Burke, D.S., Waldmann, T.A., and Perera, L.P. 2003. Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity. Proc. Natl. Acad. Sci. U. S. A. 100:3392-3397.
122. Janssen, E.M., et al. 2003. CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature. 421:852-856.
123. Sun, J.C., and Bevan, M.J. 2003. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science. 300:339-342.
124. Shedlock, D.J., and Shen, H. 2003. Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science. 300:337-339.
125. Gett, A.V., Sallusto, F., Lanzavecchia, A., and Geginat, J. 2003. T cell fitness determined by signal strength. Nat. Immunol. 4:355-360.